title: Sentinel node positive melanoma patients: prediction and prognostic significance of nonsentinel node metastases and development of a survival tree model.
abstract: BACKGROUND
  Completion lymph node dissection (CLND) following positive sentinel node biopsy (SNB) for melanoma detects additional nonsentinel node (NSN) metastases in approximately 20% of cases. This study aimed to establish whether NSN status can be predicted, to determine its effect on survival, and to develop survival tree models for the sentinel node (SN) positive population.
  
  
  METHODS
  Sydney Melanoma Unit (SMU) patients with at least 1 positive SN, meeting inclusion criteria and treated between October 1992 and June 2005, were identified from the Unit database. Survival characteristics, potential predictors of survival, and NSN status were assessed using the Kaplan-Meier method, Cox regression model, and logistic regression analyses, respectively. Classification tree analysis was performed to identify groups with distinctly different survival characteristics.
  
  
  RESULTS
  A total of 323 SN-positive melanoma patients met the inclusion criteria. On multivariate analysis, age, gender, primary tumor thickness, mitotic rate, number of positive NSNs, or total number of positive nodes were statistically significant predictors of survival. NSN metastasis, found at CLND in 19% of patients, was only predicted to a statistically significant degree by ulceration. Multivariate analyses demonstrated that survival was more closely related to number of positive NSNs than total number of positive nodes. Classification tree analysis revealed 4 prognostically distinct survival groups.
  
  
  CONCLUSIONS
  Patients with NSN metastases could not be reliably identified prior to CLND. Prognosis following CLND was more closely related to number of positive NSNs than total number of positive nodes. Classification tree analysis defined distinctly different survival groups more accurately than use of single-factor analysis.
authors.affiliation: Melanoma Institute Australia (formerly Sydney Melanoma Unit), Sydney, NSW, Australia.
authors.forename: Martin
authors.initials: M
authors.lastname: Wiener
authors.forename: Katharine M
authors.initials: KM
authors.lastname: Acland
authors.forename: Helen M
authors.initials: HM
authors.lastname: Shaw
authors.forename: Seng-Jaw
authors.initials: SJ
authors.lastname: Soong
authors.forename: Hui-Yi
authors.initials: HY
authors.lastname: Lin
authors.forename: Dung-Tsa
authors.initials: DT
authors.lastname: Chen
authors.forename: Richard A
authors.initials: RA
authors.lastname: Scolyer
authors.forename: Julie B
authors.initials: JB
authors.lastname: Winstanley
authors.forename: John F
authors.initials: JF
authors.lastname: Thompson
mesh_terms: D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology* / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000556:secondary*; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D021701:Sentinel Lymph Node Biopsy; D013223:Statistics as Topic